A Systematic Review of Clinical Features and Treatment Outcomes of Xanthoma Disseminatum.

IF 3.1 4区 医学 Q2 DERMATOLOGY
Lorena Alexandra Mija, Catherine Keying Zhu, Ilya Mukovozov
{"title":"A Systematic Review of Clinical Features and Treatment Outcomes of Xanthoma Disseminatum.","authors":"Lorena Alexandra Mija, Catherine Keying Zhu, Ilya Mukovozov","doi":"10.1177/12034754241274356","DOIUrl":null,"url":null,"abstract":"<p><p>Xanthoma disseminatum (XD) is a rare normolipidemic mucocutaneous xanthomatosis within the spectrum of cutaneous non-Langerhans histiocytosis. Managing XD poses substantial challenges, with limited available data. This study aims to comprehensively evaluate existing literature on clinical features of XD and treatment outcomes. A systematic search of MEDLINE, Embase, and PubMed was performed, using \"xanthoma disseminatum\" and \"Montgomery syndrome\" as search terms, without restrictions. Screening was performed in duplicate by 2 reviewers. One hundred fifty-one studies met the inclusion criteria, yielding 166 cases of XD (106 females, 60 males), mean age at diagnosis 35.3 years (range: 9 months-87 years). XD typically presented as yellow-to-brown coalescing papules/plaques and nodules. Distribution affects mainly the face (n = 116/166), flexures (n = 45/166), trunk (n = 65/166), and genitalia/inguinal areas (n = 63/166). Most cases (99.4%; n = 165/166) exhibited extracutaneous manifestations, including the pituitary gland and the oropharynx. Treatment options rendered low complete response rates (CRRs). Treatments with reported outcomes included surgical resection (n = 17/99), systemic steroids (n = 40/99), immunosuppressants/immunomodulators (n = 73/99), energy-based devices (n = 7/99), lipid-lowering agents (n = 24/99), cryotherapy (n = 6/99), lasers (n = 10/99), topical steroids (n = 6/99), oral retinoids (n = 2/99), and radiotherapy (n = 5/99), with CCRs of 23.5% (n = 4/17), 5.0% (n = 2/40), 9.6% (n = 7/73), 14.3% (n = 1/7), 4.2% (n = 1/24), 16.7% (n = 1/6), 10.0% (n = 1/10), 0% (n = 0/6), 0% (n = 0/2), and 0% (n = 0/5), respectively. The most promising therapy is cladribine, with the highest CRR of 27.1% (n = 6/22) and the lowest no response rate (9.1%; n = 2/22) of all reported treatments. This review confirms the high prevalence of systemic manifestations in XD. Treatment options vary widely; thus, further research is needed to establish management strategies for this challenging condition.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Medicine and Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/12034754241274356","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Xanthoma disseminatum (XD) is a rare normolipidemic mucocutaneous xanthomatosis within the spectrum of cutaneous non-Langerhans histiocytosis. Managing XD poses substantial challenges, with limited available data. This study aims to comprehensively evaluate existing literature on clinical features of XD and treatment outcomes. A systematic search of MEDLINE, Embase, and PubMed was performed, using "xanthoma disseminatum" and "Montgomery syndrome" as search terms, without restrictions. Screening was performed in duplicate by 2 reviewers. One hundred fifty-one studies met the inclusion criteria, yielding 166 cases of XD (106 females, 60 males), mean age at diagnosis 35.3 years (range: 9 months-87 years). XD typically presented as yellow-to-brown coalescing papules/plaques and nodules. Distribution affects mainly the face (n = 116/166), flexures (n = 45/166), trunk (n = 65/166), and genitalia/inguinal areas (n = 63/166). Most cases (99.4%; n = 165/166) exhibited extracutaneous manifestations, including the pituitary gland and the oropharynx. Treatment options rendered low complete response rates (CRRs). Treatments with reported outcomes included surgical resection (n = 17/99), systemic steroids (n = 40/99), immunosuppressants/immunomodulators (n = 73/99), energy-based devices (n = 7/99), lipid-lowering agents (n = 24/99), cryotherapy (n = 6/99), lasers (n = 10/99), topical steroids (n = 6/99), oral retinoids (n = 2/99), and radiotherapy (n = 5/99), with CCRs of 23.5% (n = 4/17), 5.0% (n = 2/40), 9.6% (n = 7/73), 14.3% (n = 1/7), 4.2% (n = 1/24), 16.7% (n = 1/6), 10.0% (n = 1/10), 0% (n = 0/6), 0% (n = 0/2), and 0% (n = 0/5), respectively. The most promising therapy is cladribine, with the highest CRR of 27.1% (n = 6/22) and the lowest no response rate (9.1%; n = 2/22) of all reported treatments. This review confirms the high prevalence of systemic manifestations in XD. Treatment options vary widely; thus, further research is needed to establish management strategies for this challenging condition.

散发性黄疽临床特征和治疗效果的系统性回顾。
播散性黄疽(XD)是皮肤非朗格汉斯组织细胞增生症谱系中一种罕见的正常血脂黏膜皮肤黄瘤病。由于现有数据有限,XD的治疗面临巨大挑战。本研究旨在全面评估有关XD临床特征和治疗效果的现有文献。我们使用 "散播性黄疽 "和 "蒙哥马利综合征 "作为检索词,在MEDLINE、Embase和PubMed上进行了系统性检索。筛选工作由两名审稿人重复进行。符合纳入标准的研究有 151 项,其中 XD 病例 166 例(女性 106 例,男性 60 例),诊断时的平均年龄为 35.3 岁(范围:9 个月-87 岁)。XD通常表现为黄褐色凝聚性丘疹/斑块和结节。主要分布在面部(n = 116/166)、挠部(n = 45/166)、躯干(n = 65/166)和生殖器/腹股沟部位(n = 63/166)。大多数病例(99.4%;n = 165/166)有皮外表现,包括垂体和口咽部。治疗方案的完全反应率(CRR)较低。有报道结果的治疗方法包括手术切除(n = 17/99)、全身类固醇(n = 40/99)、免疫抑制剂/免疫调节剂(n = 73/99)、能量设备(n = 7/99)、降脂药(n = 24/99)、冷冻疗法(n = 6/99)、激光(n = 10/99)、局部类固醇(n = 6/99)、口服维甲酸(n = 2/99)和放疗(n = 5/99),CCR 为 23.5%(n = 4/17)、5.0%(n = 2/40)、9.6%(n = 7/73)、14.3%(n = 1/7)、4.2%(n = 1/24)、16.7%(n = 1/6)、10.0%(n = 1/10)、0%(n = 0/6)、0%(n = 0/2)和 0%(n = 0/5)。最有希望的疗法是克拉利宾,在所有报告的疗法中,克拉利宾的CRR最高,为27.1%(n = 6/22),无反应率最低(9.1%;n = 2/22)。本综述证实了XD全身表现的高患病率。治疗方案千差万别;因此,需要进一步研究,为这种具有挑战性的疾病制定管理策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.30%
发文量
98
审稿时长
6-12 weeks
期刊介绍: Journal of Cutaneous Medicine and Surgery (JCMS) aims to reflect the state of the art in cutaneous biology and dermatology by providing original scientific writings, as well as a complete critical review of the dermatology literature for clinicians, trainees, and academicians. JCMS endeavours to bring readers cutting edge dermatologic information in two distinct formats. Part of each issue features scholarly research and articles on issues of basic and applied science, insightful case reports, comprehensive continuing medical education, and in depth reviews, all of which provide theoretical framework for practitioners to make sound practical decisions. The evolving field of dermatology is highlighted through these articles. In addition, part of each issue is dedicated to making the most important developments in dermatology easily accessible to the clinician by presenting well-chosen, well-written, and highly organized information in a format that is interesting, clearly presented, and useful to patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信